Simile’s $200M Series B Closes at $2B Valuation – A New Shockwave for APAC AI Markets

Far from Silicon Valley, the emerging APAC AI unicorn Simile has closed a $200 Million Series B round, pushing its valuation to $2 Billion.

Red‑Carpet Funding: Who’s Behind the Deal

The Series B was led by Greenoaks with participation from Index Ventures, Hanabi, Bain Capital Ventures, A\*, Factory, Definition, and CVS Health Ventures. CVS also counts among Simile’s marquee corporate customers, cementing a strategic partnership.

The Market Roots and Competitive Edge of Simile

Founded by Stanford PhD Joon Sung Park, the firm offers “simulated users” for marketing and product research. Park’s dissertation, codenamed “Smallville,” explored AI agents living full human lives – Simile translates that vision into a commercial platform.

Valuation Mechanics and Multiple Breakdown

■The jump from Series A to Series B in just 5 months signals investors’ aggressive growth expectations.

■A $100 Million Series A followed by a $200 Million Series B doubles the company’s cash runway.

■A $2 Billion valuation places Simile at a premium compared to rival Aaru, which closed at a $1 Billion headline valuation.

■The investment multiple sits above the sector’s average 10‑15x EBITDA multiple for AI‑driven market research firms.

Expanding Ecosystem Around AI‑Simulated Users

Simile’s rapid scaling underscores a burgeoning ecosystem of AI‑based user simulation and big‑data providers, attracting fresh capital and strategic alliances.

Kemal Tekin – As a strategist tracking APAC risks, Simile’s swift growth could reshape the region’s risk‑return profile. While the upside is compelling, the steep valuation warrants caution; portfolio managers should balance liquidity and volatility exposure when allocating to this emerging niche.